Your browser is no longer supported. Please, upgrade your browser.
Ocular Therapeutix, Inc.
Index- P/E- EPS (ttm)-1.25 Insider Own0.30% Shs Outstand76.55M Perf Week-2.53%
Market Cap502.60M Forward P/E- EPS next Y-0.80 Insider Trans2.22% Shs Float76.31M Perf Month-3.25%
Income-88.30M PEG- EPS next Q-0.16 Inst Own59.40% Short Float5.28% Perf Quarter-40.60%
Sales38.60M P/S13.02 EPS this Y-34.30% Inst Trans-8.34% Short Ratio3.54 Perf Half Y-55.08%
Book/sh1.14 P/B5.74 EPS next Y-6.20% ROA-37.10% Target Price21.14 Perf Year-60.41%
Cash/sh2.33 P/C2.80 EPS next 5Y- ROE-108.00% 52W Range6.37 - 24.30 Perf YTD-68.41%
Dividend- P/FCF- EPS past 5Y-8.40% ROI-50.00% 52W High-73.09% Beta1.73
Dividend %- Quick Ratio8.10 Sales past 5Y58.30% Gross Margin89.70% 52W Low2.67% ATR0.51
Employees181 Current Ratio8.10 Sales Q/Q106.80% Oper. Margin- RSI (14)36.49 Volatility5.36% 6.02%
OptionableYes Debt/Eq0.58 EPS Q/Q116.40% Profit Margin- Rel Volume0.48 Prev Close6.88
ShortableYes LT Debt/Eq0.58 EarningsNov 08 AMC Payout- Avg Volume1.14M Price6.54
Recom1.90 SMA20-6.22% SMA50-26.44% SMA200-50.52% Volume550,267 Change-4.94%
Aug-10-21Upgrade H.C. Wainwright Neutral → Buy $17
Dec-28-20Downgrade H.C. Wainwright Buy → Neutral
Dec-17-20Initiated Berenberg Buy $27
Nov-13-20Reiterated Raymond James Strong Buy $15 → $25
Aug-10-20Reiterated H.C. Wainwright Buy $10 → $13
Mar-03-20Upgrade Raymond James Outperform → Strong Buy
May-21-19Reiterated H.C. Wainwright Buy $12 → $9
May-21-19Downgrade Raymond James Strong Buy → Outperform $11 → $5
May-21-19Downgrade Cowen Outperform → Market Perform $13 → $3
Dec-03-18Reiterated Cantor Fitzgerald Overweight $22 → $24
Nov-15-18Initiated Raymond James Strong Buy $10
Sep-07-18Initiated Piper Jaffray Overweight
Oct-24-17Initiated Guggenheim Buy $12
Jul-26-17Initiated H.C. Wainwright Buy $10
Jul-12-17Reiterated Cantor Fitzgerald Overweight $35 → $21
Jun-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17Initiated Cantor Fitzgerald Overweight $35
Nov-15-16Reiterated RBC Capital Mkts Outperform $30 → $32
Aug-11-16Initiated JMP Securities Mkt Outperform
Feb-17-16Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-20-21 06:09AM  
Nov-15-21 08:00AM  
Nov-09-21 01:17PM  
Nov-08-21 07:35PM  
Nov-05-21 11:44AM  
Nov-01-21 08:00AM  
Oct-29-21 04:01PM  
Oct-28-21 03:05PM  
Oct-25-21 03:13PM  
Oct-24-21 10:00AM  
Oct-22-21 03:30PM  
Oct-17-21 08:35PM  
Oct-11-21 12:30PM  
Sep-28-21 08:00AM  
Sep-22-21 08:00AM  
Sep-13-21 06:45AM  
Sep-07-21 08:00AM  
Sep-06-21 12:18PM  
Aug-22-21 07:38AM  
Aug-21-21 06:21AM  
Aug-10-21 08:00AM  
Aug-09-21 05:25PM  
Aug-05-21 04:01PM  
Aug-02-21 03:01PM  
Jul-29-21 08:00AM  
Jul-28-21 08:00AM  
Jul-27-21 10:00AM  
Jul-23-21 08:00AM  
Jul-22-21 04:01PM  
Jul-11-21 08:43AM  
Jul-06-21 06:44AM  
Jun-29-21 08:00AM  
May-26-21 08:00AM  
May-20-21 08:46AM  
May-07-21 02:12AM  
May-05-21 04:01PM  
May-03-21 06:16PM  
Apr-28-21 08:00AM  
Apr-20-21 06:02AM  
Apr-01-21 09:21AM  
Mar-11-21 05:25PM  
Mar-05-21 08:15AM  
Mar-04-21 04:01PM  
Mar-01-21 07:00AM  
Feb-25-21 08:00AM  
Feb-24-21 08:00AM  
Feb-19-21 04:49AM  
Feb-17-21 07:56AM  
Feb-16-21 06:55AM  
Feb-12-21 08:00AM  
Feb-04-21 04:01PM  
Jan-20-21 08:00AM  
Jan-07-21 08:00AM  
Jan-06-21 11:24AM  
Dec-28-20 08:00AM  
Dec-23-20 02:31PM  
Dec-22-20 08:45AM  
Dec-21-20 05:39AM  
Dec-15-20 09:47PM  
Dec-14-20 04:13PM  
Dec-11-20 10:55PM  
Nov-23-20 08:00AM  
Nov-11-20 09:00AM  
Nov-09-20 04:01PM  
Nov-06-20 02:13AM  
Nov-05-20 05:35PM  
Nov-04-20 08:00AM  
Oct-30-20 08:00AM  
Oct-29-20 12:35PM  
Oct-23-20 07:00AM  
Oct-22-20 07:32AM  
Oct-14-20 06:30AM  
Oct-13-20 05:01PM  
Oct-08-20 08:00AM  
Oct-07-20 08:00AM  
Oct-06-20 08:00AM  
Sep-29-20 08:00AM  
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mattessich Antony C.President and CEOAug 20Buy9.895,00049,450102,900Aug 24 08:49 AM
LINDSTROM RICHARD L MDDirectorMay 20Sale14.3010,000143,00090,000May 21 09:05 PM
PEACOCK BRUCEDirectorDec 03Option Exercise5.0925,000127,18025,000Dec 07 09:30 PM